Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Zheng Quan Toh, Jennie Kosasih, Fiona M Russell, Suzanne M Garland, Edward K Mulholland & Paul V Licciardi. (2019) Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. Infection and Drug Resistance 12, pages 1951-1967.
Read now
Read now
Tommy R. Buchanan, Whitney S. Graybill & Jennifer Young Pierce. (2016) Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines. Human Vaccines & Immunotherapeutics 12:6, pages 1352-1356.
Read now
Read now
Mark H Einstein, Peter Takacs, Archana Chatterjee, Rhoda S Sperling, Nahida Chakhtoura, Mark M Blatter, Jacob Lalezari, Marie-Pierre David, Lan Lin, Frank Struyf & Gary Dubin. (2014) Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial. Human Vaccines & Immunotherapeutics 10:12, pages 3435-3445.
Read now
Read now
Franco M Buonaguro, Maria Lina Tornesello & Luigi Buonaguro. (2011) New adjuvants in evolving vaccine strategies. Expert Opinion on Biological Therapy 11:7, pages 827-832.
Read now
Read now
Articles from other publishers (43)
Tsukasa Seya, Masashi Shingai, Tomomi Kawakita & Misako Matsumoto. (2023) Two Modes of Th1 Polarization Induced by Dendritic-Cell-Priming Adjuvant in Vaccination. Cells 12:11, pages 1504.
Crossref
Crossref
Halie M. Rando, Ronan Lordan, Alexandra J. Lee, Amruta Naik, Nils Wellhausen, Elizabeth Sell, Likhitha Kolla, Anthony Gitter, Casey S. Greene, Vikas Bansal, John P. Barton, Simina M. Boca, Joel D. Boerckel, Christian Brueffer, James Brian Byrd, Stephen Capone, Shikta Das, Anna Ada Dattoli, John J. Dziak, Jeffrey M. Field, Soumita Ghosh, Anthony Gitter, Rishi Raj Goel, Casey S. Greene, Marouen Ben Guebila, Daniel S. Himmelstein, Fengling Hu, Nafisa M. Jadavji, Jeremy P. Kamil, Sergey Knyazev, Likhitha Kolla, Alexandra J. Lee, Ronan Lordan, Tiago Lubiana, Temitayo Lukan, Adam L. MacLean, David Mai, Serghei Mangul, David Manheim, Lucy D’Agostino McGowan, Jesse G. Meyer, Ariel I. Mundo, Amruta Naik, YoSon Park, Dimitri Perrin, Yanjun Qi, Diane N. Rafizadeh, Bharath Ramsundar, Halie M. Rando, Sandipan Ray, Michael P. Robson, Vincent Rubinetti, Elizabeth Sell, Lamonica Shinholster, Ashwin N. Skelly, Yuchen Sun, Yusha Sun, Gregory L. Szeto, Ryan Velazquez, Jinhui Wang & Nils Wellhausen. (2023) Application of Traditional Vaccine Development Strategies to SARS-CoV-2. mSystems 8:2.
Crossref
Crossref
Cal Koger-Pease, Dilhan J. Perera & Momar Ndao. (2023) Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections. Pharmaceuticals 16:3, pages 334.
Crossref
Crossref
Hoorieh Soleimanjahi & Seyed-Mahmood Seyed-Khorrami. 2023. Cancer Nanotechnology. Cancer Nanotechnology
229
252
.
Nilkanth Pant, Himanshu Deol, Abhay Chauhan, Ankit Mehra, Atul Singh & Bhupinder Kaur. (2021) Animal Shelter, Vaccination and Welfare. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, pages 14-24.
Crossref
Crossref
Andres Alfredo Pech-Cervantes, Muhammad Irfan, Zaira Magdalena Estrada-Reyes & Ibukun Michael Ogunade. (2020) Recombinant Technologies to Improve Ruminant Production Systems: The Past, Present and Future. Processes 8:12, pages 1633.
Crossref
Crossref
Yuemei Hu, Xiang Zhang, Yilin He, Zhilong Ma, Yan Xie, Xiangbin Lu, Yabin Xu, Yanqiu Zhang, Yunyu Jiang, Hui Xiao, Frank Struyf, Nicolas Folschweiller, Johny Jiang, Sylviane Poncelet, Naveen Karkada, Archana Jastorff & Dorota Borys. (2020) Long‐term persistence of immune response to the AS04‐adjuvanted HPV‐16/18 vaccine in Chinese girls aged 9‐17 years: Results from an 8‐9‐year follow‐up phase III open‐label study. Asia-Pacific Journal of Clinical Oncology 16:6, pages 392-399.
Crossref
Crossref
Kaoutar Anouar Tadlaoui, Najwa Hassou, Bahia Bennani & Moulay Mustapha Ennaji. 2020. Emerging and Reemerging Viral Pathogens. Emerging and Reemerging Viral Pathogens
539
570
.
Zheng Quan Toh, Jennie Kosasih, Fiona M. Russell, Rita Reyburn, James Fong, Evelyn Tuivaga, Felisita T. Ratu, Cattram D. Nguyen, Silivia Matanitobua, Lien Anh Ha Do, Trevelyan Menheniott, Ian H. Frazer, Suzanne M. Garland, Edward Kim Mulholland & Paul V. Licciardi. (2019) Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules. Vaccines 7:4, pages 200.
Crossref
Crossref
Béatrice Laupèze, Caroline Hervé, Alberta Di Pasquale & Fernanda Tavares Da Silva. (2019) Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood. Vaccine 37:38, pages 5670-5680.
Crossref
Crossref
Sneha Ratnapriya, Keerti, Amogh A. Sahasrabuddhe & Anuradha Dube. (2019) Visceral leishmaniasis: An overview of vaccine adjuvants and their applications. Vaccine 37:27, pages 3505-3519.
Crossref
Crossref
Ralf Wagner & Eberhard Hildt. (2019) Zusammensetzung und Wirkmechanismen von Adjuvanzien in zugelassenen viralen ImpfstoffenComposition and mode of action of adjuvants in licensed viral vaccines. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 62:4, pages 462-471.
Crossref
Crossref
Tomoya Hayashi, Masatoshi Momota, Etsushi Kuroda, Takato Kusakabe, Shingo Kobari, Kotaro Makisaka, Yoshitaka Ohno, Yusuke Suzuki, Fumika Nakagawa, Michelle S. J. Lee, Cevayir Coban, Risako Onodera, Taishi Higashi, Keiichi Motoyama, Ken J. Ishii & Hidetoshi Arima. (2018) DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination. Frontiers in Immunology 9.
Crossref
Crossref
Ali M. Harandi. (2018) Systems analysis of human vaccine adjuvants. Seminars in Immunology 39, pages 30-34.
Crossref
Crossref
Tatyana A. Kuznetsova, Elena V. Persiyanova, Svetlana P. Ermakova, Maxim Yu. Khotimchenko & Natalya N. Besednova. (2018) The Sulfated Polysaccharides of Brown Algae and Products of Their Enzymatic Transformation as Potential Vaccine Adjuvants. Natural Product Communications 13:8, pages 1934578X1801300.
Crossref
Crossref
Ligia A. Pinto, Joakim Dillner, Simon Beddows & Elizabeth R. Unger. (2018) Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine 36:32, pages 4792-4799.
Crossref
Crossref
Ewa Oleszycka, Sean McCluskey, Fiona A. Sharp, Natalia Muñoz-Wolf, Emily Hams, Aoife L. Gorman, Padraic G. Fallon & Ed C. Lavelle. (2018) The vaccine adjuvant alum promotes IL-10 production that suppresses Th1 responses. European Journal of Immunology 48:4, pages 705-715.
Crossref
Crossref
Susan L. Baldwin, Fan-Chi Hsu, Neal Van Hoeven, Emily Gage, Brian Granger, Jeffrey A. Guderian, Sasha E. Larsen, Erica C. Lorenzo, Laura Haynes, Steven G. Reed & Rhea N. Coler. (2018) Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection. Frontiers in Immunology 9.
Crossref
Crossref
Qi Yu, Xiaochun Wang & Xionglin Fan. (2017) A New Adjuvant MTOM Mediates Mycobacterium tuberculosis Subunit Vaccine to Enhance Th1-Type T Cell Immune Responses and IL-2+ T Cells. Frontiers in Immunology 8.
Crossref
Crossref
Muhammad Shafique, Muhammad Hidayat Rasool & Mohsin Khurshid. (2017) Respiratory syncytial virus: an overview of infection biology and vaccination strategies. Future Virology 12:5, pages 297-313.
Crossref
Crossref
Sérgio Jorge & Odir Antônio Dellagostin. (2017) The development of veterinary vaccines: a review of traditional methods and modern biotechnology approaches. Biotechnology Research and Innovation 1:1, pages 6-13.
Crossref
Crossref
Tom Y.-H. Wu. (2016) Strategies for designing synthetic immune agonists. Immunology 148:4, pages 315-325.
Crossref
Crossref
Sonja T. H. M. Kolanowski, Suzanne N. Lissenberg-Thunnissen, Diba Emal, S. Marieke van Ham & Anja ten Brinke. (2016) Monophosphoryl lipid A-induced pro-inflammatory cytokine expression does not require CD14 in primary human dendritic cells. Inflammation Research 65:6, pages 449-458.
Crossref
Crossref
Harry B. Greenberg & Philip R. Dormitzer. 2016. Encyclopedia of Immunobiology. Encyclopedia of Immunobiology
389
395
.
Zheng Quan Toh, Paul V. Licciardi, James Fong, Suzanne M. Garland, Sepehr N. Tabrizi, Fiona M. Russell & Edward K. Mulholland. (2015) Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art. Vaccine 33:39, pages 5042-5050.
Crossref
Crossref
Thorunn Olafsdottir, Madelene Lindqvist & Ali M. Harandi. (2015) Molecular signatures of vaccine adjuvants. Vaccine 33:40, pages 5302-5307.
Crossref
Crossref
Pramila Walpita, Lisa M. Johns, Ravi Tandon & Martin L. Moore. (2015) Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract. PLOS ONE 10:7, pages e0130755.
Crossref
Crossref
John T. Schiller & Douglas R. Lowy. (2015) Raising Expectations For Subunit Vaccine. The Journal of Infectious Diseases 211:9, pages 1373-1375.
Crossref
Crossref
John T Schiller & Martin Müller. (2015) Next generation prophylactic human papillomavirus vaccines. The Lancet Oncology 16:5, pages e217-e225.
Crossref
Crossref
Charlotte N Maughan, Stephen G Preston & Gareth R Williams. (2015) Particulate inorganic adjuvants: recent developments and future outlook. Journal of Pharmacy and Pharmacology 67:3, pages 426-449.
Crossref
Crossref
Sujin LeeMinh Trang Nguyen. (2015) Recent Advances of Vaccine Adjuvants for Infectious Diseases. Immune Network 15:2, pages 51.
Crossref
Crossref
Jianchun Wei, Hui Chen & Jing An. (2014) Recent progress in dengue vaccine development. Virologica Sinica 29:6, pages 353-363.
Crossref
Crossref
Luisa Barzon, Laura Squarzon, Serena Masiero, Monia Pacenti, Giorgia Marcati, Barbara Mantelli, Liliana Gabrielli, Maria Grazia Pascucci, Tiziana Lazzarotto, Antonella Caputo & Giorgio Palù. (2014) Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. Vaccine 32:41, pages 5357-5362.
Crossref
Crossref
Usa Thisyakorn & Chule Thisyakorn. (2013) Latest developments and future directions in dengue vaccines. Therapeutic Advances in Vaccines 2:1, pages 3-9.
Crossref
Crossref
Rajesh K. Gupta. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
32
.
Tobias Kamphuis, Toon Stegmann, Tjarko Meijerhof, Jan Wilschut & Aalzen de Haan. (2013) A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats. Influenza and Other Respiratory Viruses 7:6, pages 1227-1236.
Crossref
Crossref
Tobias Kamphuis, Muhammad Shafique, Tjarko Meijerhof, Toon Stegmann, Jan Wilschut & Aalzen de Haan. (2013) Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats. Vaccine 31:17, pages 2169-2176.
Crossref
Crossref
Scott B. Halstead & Stephen J. Thomas. 2013. Vaccines. Vaccines
1042
1051
.
James H. Conway & Roman Aydiko Ayele. 2013. Vaccinophobia and Vaccine Controversies of the 21st Century. Vaccinophobia and Vaccine Controversies of the 21st Century
213
233
.
John T. Schiller, Xavier Castellsagué & Suzanne M. Garland. (2012) A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines. Vaccine 30, pages F123-F138.
Crossref
Crossref
Tobias Kamphuis, Tjarko Meijerhof, Toon Stegmann, Julia Lederhofer, Jan Wilschut & Aalzen de Haan. (2012) Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice. PLoS ONE 7:5, pages e36812.
Crossref
Crossref
Yong-shan Wang, Wei Ouyang, Xiao-juan Liu, Kong-wang He, Sheng-qing Yu, Hai-bin Zhang, Hong-jie Fan & Cheng-ping Lu. (2012) Virus-like particles of hepatitis B virus core protein containing five mimotopes of infectious bursal disease virus (IBDV) protect chickens against IBDV. Vaccine 30:12, pages 2125-2130.
Crossref
Crossref
Camilla Foged, Jon Hansen & Else Marie Agger. (2012) License to kill: Formulation requirements for optimal priming of CD8+ CTL responses with particulate vaccine delivery systems. European Journal of Pharmaceutical Sciences 45:4, pages 482-491.
Crossref
Crossref